Comment on the PLENTY study on pembrolizumab-lenvatinib as neoadjuvant therapy in HCC prior to liver transplantation.

Int J Surg · 2025 · PMC12695365 · PMID 40844314

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The highly significant pathological necrosis rate (60%) failed to translate into durable survival, indicating that biological aggressiveness in advanced HCC is not fully mitigated by this approach.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.